In Brief: Thermo Cardiosystems HeartMate
This article was originally published in The Gray Sheet
Executive Summary
Thermo Cardiosystems HeartMate: Left ventricular-assist system is implanted for the first time in the U.K. as a permanent alternative to heart transplant. The procedure is the first of a "series of implants in which the electric LVAS will be used to permanently take over the pumping function of natural hearts too weak to beat adequately on their own," the company says. Woburn, Massachusetts-based Thermo Cardiosystems says it is "actively working" with FDA to begin a study of the HeartMate as a "permanent alternative to other medical treatments for patients who do not qualify for transplants." HeartMate was approved by FDA in October 1994 for use as a bridge-to-heart transplant ("The Gray Sheet" Oct. 10, 1994, p. 1)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.